129 related articles for article (PubMed ID: 20001562)
1. HER-dimerization inhibitors: evaluating pertuzumab in women's cancers.
Kristjansdottir K; Dizon D
Expert Opin Biol Ther; 2010 Feb; 10(2):243-50. PubMed ID: 20001562
[TBL] [Abstract][Full Text] [Related]
2. Pertuzumab for the treatment of ovarian cancer.
Langdon SP; Faratian D; Nagumo Y; Mullen P; Harrison DJ
Expert Opin Biol Ther; 2010 Jul; 10(7):1113-20. PubMed ID: 20465533
[TBL] [Abstract][Full Text] [Related]
3. Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.
Chung C; Lam MS
Am J Health Syst Pharm; 2013 Sep; 70(18):1579-87. PubMed ID: 23988598
[TBL] [Abstract][Full Text] [Related]
4. Pertuzumab: development beyond breast cancer.
Barthélémy P; Leblanc J; Goldbarg V; Wendling F; Kurtz JE
Anticancer Res; 2014 Apr; 34(4):1483-91. PubMed ID: 24692675
[TBL] [Abstract][Full Text] [Related]
5. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
De Mattos-Arruda L; Cortes J
Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
[TBL] [Abstract][Full Text] [Related]
6. Pertuzumab: optimizing HER2 blockade.
Metzger-Filho O; Winer EP; Krop I
Clin Cancer Res; 2013 Oct; 19(20):5552-6. PubMed ID: 23942091
[TBL] [Abstract][Full Text] [Related]
7. Rationale for a phase II trial of pertuzumab, a HER-2 dimerization inhibitor, in patients with non-small cell lung cancer.
Johnson BE; Jänne PA
Clin Cancer Res; 2006 Jul; 12(14 Pt 2):4436s-4440s. PubMed ID: 16857824
[TBL] [Abstract][Full Text] [Related]
8. HER dimerization inhibitors: developing pertuzumab as an anticancer agent in women's oncology.
Dizon DS; Makhija S
Expert Opin Drug Discov; 2008 Nov; 3(11):1363-9. PubMed ID: 23496170
[TBL] [Abstract][Full Text] [Related]
9. HER3 mRNA as a predictive biomarker in anticancer therapy.
Amler LC
Expert Opin Biol Ther; 2010 Sep; 10(9):1343-55. PubMed ID: 20695834
[TBL] [Abstract][Full Text] [Related]
10. Pertuzumab in gastrointestinal cancer.
Oh DY; Bang YJ
Expert Opin Biol Ther; 2016; 16(2):243-53. PubMed ID: 26619359
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy.
Rocca A; Andreis D; Fedeli A; Maltoni R; Sarti S; Cecconetto L; Pietri E; Schirone A; Bravaccini S; Serra P; Farolfi A; Amadori D
Expert Opin Drug Metab Toxicol; 2015; 11(10):1647-63. PubMed ID: 26307328
[TBL] [Abstract][Full Text] [Related]
12. [Pertuzumab and solid tumors: perspectives].
Barthélémy P; Leblanc J; Wendling F; Wissler MP; Bergerat JP
Bull Cancer; 2014 Dec; 101(12):1114-21. PubMed ID: 25532690
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of single-agent pertuzumab, a human epidermal receptor dimerization inhibitor, in patients with non small cell lung cancer.
Herbst RS; Davies AM; Natale RB; Dang TP; Schiller JH; Garland LL; Miller VA; Mendelson D; Van den Abbeele AD; Melenevsky Y; de Vries DJ; Eberhard DA; Lyons B; Lutzker SG; Johnson BE
Clin Cancer Res; 2007 Oct; 13(20):6175-81. PubMed ID: 17947484
[TBL] [Abstract][Full Text] [Related]
14. Update on HER-kinase-directed therapy in prostate cancer.
Gross ME; Jo S; Agus DB
Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
[TBL] [Abstract][Full Text] [Related]
15. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
[TBL] [Abstract][Full Text] [Related]
16. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.
Gordon MS; Matei D; Aghajanian C; Matulonis UA; Brewer M; Fleming GF; Hainsworth JD; Garcia AA; Pegram MD; Schilder RJ; Cohn DE; Roman L; Derynck MK; Ng K; Lyons B; Allison DE; Eberhard DA; Pham TQ; Dere RC; Karlan BY
J Clin Oncol; 2006 Sep; 24(26):4324-32. PubMed ID: 16896006
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of functional HER family members increases the sensitivity to docetaxel in human ovarian cancer cell lines.
Bijman MN; van Berkel MP; Kok M; Janmaat ML; Boven E
Anticancer Drugs; 2009 Jul; 20(6):450-60. PubMed ID: 19369859
[TBL] [Abstract][Full Text] [Related]
18. Modulation of HER3 is a marker of dynamic cell signaling in ovarian cancer: implications for pertuzumab sensitivity.
Nagumo Y; Faratian D; Mullen P; Harrison DJ; Hasmann M; Langdon SP
Mol Cancer Res; 2009 Sep; 7(9):1563-71. PubMed ID: 19737968
[TBL] [Abstract][Full Text] [Related]
19. Suppression of HER2/HER3-mediated growth of breast cancer cells with combinations of GDC-0941 PI3K inhibitor, trastuzumab, and pertuzumab.
Yao E; Zhou W; Lee-Hoeflich ST; Truong T; Haverty PM; Eastham-Anderson J; Lewin-Koh N; Gunter B; Belvin M; Murray LJ; Friedman LS; Sliwkowski MX; Hoeflich KP
Clin Cancer Res; 2009 Jun; 15(12):4147-56. PubMed ID: 19509167
[TBL] [Abstract][Full Text] [Related]
20. Risk of rash with the anti-HER2 dimerization antibody pertuzumab: a meta-analysis.
Drucker AM; Wu S; Dang CT; Lacouture ME
Breast Cancer Res Treat; 2012 Sep; 135(2):347-54. PubMed ID: 22782294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
